8-K: Zymeworks Secures $250M Royalty Financing for Ziihera

Zymeworks has secured $250 million in non-recourse royalty-backed financing from Royalty Pharma, leveraging future Ziihera royalties to bolster its balance sheet and fund strategic initiatives.

Summary

• Zymeworks BC Inc., a subsidiary of Zymeworks Inc., sold 30% of future royalty payments related to Ziihera (zanidatamab-hrii) to Zymeworks Royalty Limited Partnership, a special purpose entity, for $250.0 million.
• The special purpose entity subsequently entered into a Loan Agreement with Royalty Pharma as administrative agent and lender for an aggregate principal amount of $250.0 million.
• The loan bears a fixed interest rate and matures on December 31, 2042, with the total amount payable to Lenders being approximately $481.3 million by maturity.
• An early repayment option exists, where if the loan is repaid in full on or before December 31, 2033, the amount payable is $412.5 million.
• Zymeworks will retain 70% of royalties on Ziihera annual net sales, with full royalty rights reverting to the company once the loan and other amounts payable to Royalty Pharma have been repaid in full.
• All earned regulatory and commercial milestone payments under the Jazz and BeOne agreements, totaling up to $1.5 billion, will be retained by Zymeworks.
• The financing is non-recourse to Zymeworks Inc. and Zymeworks BC, with payment obligations limited to the special purpose entity and secured by the Royalty Interest and pledged equity interests.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strategically sound move to secure significant non-dilutive capital and extend operational runway, enabling shareholder-friendly actions like share repurchases, despite the substantial cost of capital associated with royalty monetization.

Positives

• Secured $250 million in non-dilutive capital, strengthening the balance sheet without issuing new equity.
• The funding supports Zymeworks' stock repurchase program, allowing the company to buy back shares at what it believes is a compelling discount to intrinsic value.
• Provides additional capacity to pursue potential strategic acquisitions that meet rigorous risk-adjusted return criteria.
• Extends Zymeworks' cash runway beyond 2028, enhancing financial stability and operational flexibility.
• Zymeworks retains 70% of Ziihera royalties during the repayment period and full royalty rights revert upon loan repayment.
• All significant regulatory and commercial milestone payments, totaling up to $1.5 billion, are retained by Zymeworks.

Negatives

• Zymeworks has monetized 30% of its future Ziihera royalty stream, reducing its direct participation in the drug's commercial success during the repayment period.
• The total repayment amount to Royalty Pharma is significantly higher than the initial $250 million received, ranging from $412.5 million (if repaid by December 31, 2033) to approximately $481.3 million (by December 31, 2042), representing a high cost of capital.
• Zymeworks BC is restricted from certain actions regarding the Covered Agreements and Ziihera-specific intellectual property without the consent of the Subsidiary and Royalty Pharma, potentially limiting future strategic flexibility related to Ziihera.

Risks

• Zymeworks may not realize the anticipated benefits of the royalty-backed note transaction or deploy the proceeds in a way that enhances shareholder returns.
• Ziihera (zanidatamab-hrii) may fail in development, may not receive required regulatory approvals, or may be delayed to a point where it is not commercially viable.
• Zymeworks may not achieve milestones or receive additional payments under its collaborations with Jazz and BeOne.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials for Ziihera or other product candidates.
• The commercialization of zanidatamab may not be successful, impacting the royalty streams available for loan repayment.
• Zymeworks' assumptions and estimates regarding its financial condition, future financial performance, and estimated cash runway may be incorrect.
• Inability to maintain or enter into new partnerships or strategic collaborations could impact future revenue streams.

Future Outlook

Zymeworks anticipates using the $250 million in non-dilutive capital to strengthen its balance sheet, support its stock repurchase program, pursue potential strategic acquisitions, and extend its cash runway beyond 2028. The company believes this disciplined capital allocation strategy will increase the underlying value of the business and reduce share count over time, leading to higher long-term shareholder value. Zymeworks expects continued development and commercialization of Ziihera by its partners, Jazz and BeOne, leveraging its Breakthrough Therapy and Fast Track designations.

Management Comments

• "This strategic funding provides non-dilutive capital that enhances our flexibility to continue repurchasing shares at current prices, which we believe represents a compelling discount to our estimate of intrinsic value." Kenneth Galbraith, Chair, CEO and Acting CFO of Zymeworks.
• "It also gives us additional capacity to pursue strategic acquisitions that meet our rigorous risk-adjusted return criteria and fund our cash runway beyond 2028." Kenneth Galbraith.
• "We believe this disciplined capital allocation strategy will increase the underlying value of the business, while thoughtfully reducing our share count over time, setting us up for higher long-term shareholder value." Kenneth Galbraith.
• "We are delighted to enter into this royalty funding agreement with Zymeworks on royalties from Ziihera, a therapy with the potential to meaningfully change the treatment landscape for patients with HER2-positive gastric and biliary tract cancers." Pablo Legorreta, CEO and Chairman of the Board of Royalty Pharma.
• "The recent clinical results from HERIZON-GEA-01 for Ziihera in first-line metastatic gastroesophageal adenocarcinoma (mGEA) underscore its potential to prolong survival in a disease with poor prognosis and urgent need of new treatment options." Pablo Legorreta.

Industry Context

StockSavvy.ai notes that royalty monetization deals are a common strategy in the biopharmaceutical industry, particularly for companies with promising late-stage or approved assets like Ziihera. This type of non-dilutive financing allows companies to access significant capital without impacting their equity structure, which is often favored by investors. Royalty Pharma's participation underscores the perceived value and commercial potential of Ziihera, especially given its recent clinical results in mGEA and existing accelerated approval for BTC. This transaction aligns with a broader industry trend where specialized financing firms provide capital in exchange for future revenue streams, enabling biotech companies to fund R&D, strategic growth, or shareholder return initiatives.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Benefit from non-dilutive capital, extended cash runway, potential share repurchases, and strategic acquisitions aimed at increasing long-term shareholder value. However, they will see 30% of Ziihera royalties diverted until the loan is repaid.
• Employees: Enhanced financial stability and extended cash runway may provide greater job security and support ongoing R&D efforts.
• Customers/Patients: Continued development and potential broader access to Ziihera through partners Jazz and BeOne, supported by Zymeworks' strengthened financial position.

Next Steps

• Continue supporting the commercialization and development of Ziihera by partners Jazz Pharmaceuticals and BeOne Medicines.
• Implement the stock repurchase program, leveraging the new capital.
• Evaluate and pursue potential strategic acquisitions that meet the company's risk-adjusted return criteria.
• Advance Zymeworks' diverse pipeline of novel, multifunctional biotherapeutics.

Key Dates

Recommendation

The non-dilutive nature of this $250 million financing significantly strengthens Zymeworks' balance sheet and extends its cash runway beyond 2028, providing crucial operational flexibility. Management explicitly plans to use this capital for share repurchases, which they believe are at a discount to intrinsic value, and for strategic acquisitions, both of which are typically value-accretive for shareholders. While the cost of capital for the royalty monetization is high, the immediate financial stability and strategic optionality it provides, coupled with Zymeworks retaining 70% of Ziihera royalties and all milestone payments, positions the company favorably for future growth and shareholder returns. This move de-risks the company's near-term financial outlook and allows it to focus on pipeline development and value creation.

Keywords

Zymeworks, Royalty Pharma, Ziihera, zanidatamab, royalty financing, non-dilutive capital, biopharmaceutical, HER2, oncology, capital raise, Jazz Pharmaceuticals, BeOne Medicines